Nippon Shinyaku Co., Ltd.
18 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 7 name spellings.
15
Ending by 2030
Feb 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 20, 2026The maintenance fee for Crystals (US 11,680,055) comes due Dec 20, 2026. Unpaid by Jun 21, 2027, it lapses early.
- 1 fee due Jun 22, 2027The maintenance fee for Heterocyclic derivative and pharmaceutical drug (US 9,216,968) comes due Jun 22, 2027. Unpaid by Dec 22, 2027, it lapses early.
- 1 fee due Aug 18, 2027The maintenance fee for Antisense nucleic acid for treating amyotrophy (US 10,563,199) comes due Aug 18, 2027. Unpaid by Feb 18, 2028, it lapses early.
- 1 fee due Sep 15, 2027The maintenance fee for Use of Form-I Crystal of 2-{4-[N-(5,6-Diphenylpyrazin-2-YL)-N-ISOPROPYLAMINO]BUTYLOXY}-N-(METHYLSULFONYL)ACETAMIDE (US 9,284,280) comes due Sep 15, 2027. Unpaid by Mar 15, 2028, it lapses early.
- 3 fees due Nov 14 to 17, 2027 · next Nov 14
Recent changes
- 1 of the patents on this record was granted since Aug 20, 2026
- 1 term has ended since Aug 20, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,820,629 | Galactose derivative, drug carrier and medicinal composition In force · From the USPTO record | In force | From the USPTO record | |
| US 8,617,603 | Coated tablet In force · From the USPTO record | In force | From the USPTO record | |
| US 8,691,970 | Phosphoramidite compound and method for producing oligo-RNA In force · From the USPTO record | In force | From the USPTO record | |
| US 8,158,775 | Method for detaching protecting group on nucleic acid In force · From the USPTO record | In force | From the USPTO record | |
| US 8,158,774 | Method for introducing a nucleic-acid protecting group In force · From the USPTO record | In force | From the USPTO record | |
| US 8,889,693 | Fibrosis inhibitor In force · From the USPTO record | In force | From the USPTO record | |
| US 8,282,956 | Coated tablet In force · From the USPTO record | In force | From the USPTO record | |
| US 8,466,255 | Polyethylene glycol derivative In force · From the USPTO record | In force | From the USPTO record | |
| US 8,394,793 | Therapeutic agent for inflammatory bowel disease In force · From the USPTO record | In force | From the USPTO record | |
| US RE46,364 | Fibrosis inhibitor In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 44: 18 patents in force now held by others · 41 lapsed for an unpaid fee · 137 ended at full term · 1 surrendered on reissue. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
20 pending · 14 abandoned · 28 no status recorded